Predictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease

Background: Chronic obstructive pulmonary disease (COPD) is an insidiously starting disease. Early detection has high priority because of the possibility of early implementation of smoking cessation interventions. An evidence based model for case finding of COPD is not yet available. Objective: To describe the early development of COPD, and to assess the predictive value of early signs (respiratory symptoms, lung function below the normal range, reversibility). Design and methods: In a prospective study, based in general practice, formerly undiagnosed subjects (n = 464) were assessed at baseline and at 5 years for respiratory symptoms and pulmonary function. Odds ratios for early signs were calculated (adjusted for age, gender, pack-years at baseline and smoking behaviour during follow-up), and defined as possible indicators of disease progression. Results: Over a 5 year period, the percentage of subjects with obstruction increased from 7.5% (n = 35) at baseline to 24.8% (n = 115) at 5 years. The presence of mild early signs and lung function below the normal range at baseline were related to an increased risk of developing mild to moderate COPD (GOLD I: OR 1.87 (95% CI 1.22 to 2.87); GOLD II: OR 2.08 (95% CI 1.29 to 3.37) to 2.54 (95% CI 1.25 to 5.19)) at 5 years. Conclusion: Lung function below the normal range and early respiratory signs predict the development and progression of COPD.

[1]  T. Sandström,et al.  Seven-year cumulative incidence of COPD in an age-stratified general population sample. , 2006, Chest.

[2]  D. Price,et al.  Misdiagnosis of COPD and Asthma in Primary Care Patients 40 Years of Age and Over , 2006, The Journal of asthma : official journal of the Association for the Care of Asthma.

[3]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[4]  C. van Weel,et al.  Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program. , 2004, Chest.

[5]  S. Rennard.  Treatment of stable chronic obstructive pulmonary disease , 2004, The Lancet.

[6]  M. Decramer,et al.  Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. , 2004, Chest.

[7]  P. Sterk.  Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 , 2004, European Respiratory Journal.

[8]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[9]  P. Jakobsson,et al.  Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[10]  F Neukirch,et al.  An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages , 2004, Thorax.

[11]  M. Partridge.  COPD in the ECRHS , 2004 .

[12]  C. van Weel,et al.  Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. , 2003, Respiratory medicine.

[13]  D. Mannino.  Chronic obstructive pulmonary disease: definition and epidemiology. , 2003, Respiratory care.

[14]  B. Celli,et al.  Population impact of different definitions of airway obstruction , 2003, European Respiratory Journal.

[15]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[16]  D. Coultas,et al.  Undiagnosed airflow obstruction: prevalence and implications , 2003, Current opinion in pulmonary medicine.

[17]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[18]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[19]  G. Wesseling,et al.  Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study , 2002, BMJ : British Medical Journal.

[20]  C. van Weel,et al.  The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. , 2001, American journal of respiratory and critical care medicine.

[21]  M P Rutten-van Mölken,et al.  The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. , 2001, American journal of respiratory and critical care medicine.

[22]  D. Coultas,et al.  The health impact of undiagnosed airflow obstruction in a national sample of United States adults. , 2001, American journal of respiratory and critical care medicine.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[24]  J. Zieliński,et al.  Early detection of COPD in a high-risk population using spirometric screening. , 2001, Chest.

[25]  Dirkje S Postma,et al.  Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study , 2000, The Lancet.

[26]  C van Weel,et al.  Family practice research networks. Experiences from 3 countries. , 2000, The Journal of family practice.

[27]  D. Sackett,et al.  The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. , 2000, JAMA.

[28]  C. Weel,et al.  Underpresentation of shortness of breath in the general population: Results of the DIMCA programme , 1999 .

[29]  C. van Weel,et al.  Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. , 1998, American journal of respiratory and critical care medicine.

[30]  C. van Weel,et al.  Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? , 1996, The British journal of general practice : the journal of the Royal College of General Practitioners.

[31]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[32]  B. Rosner,et al.  Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. , 1995, American journal of respiratory and critical care medicine.

[33]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[34]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[35]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[36]  C. van Weel,et al.  Does the continuous use of bronchodilators mask the progression of asthma or chronic bronchitis? , 1992, Family practice.

[37]  A. Woolcock,et al.  Rate of decline of lung function in subjects with asthma. , 1987, European journal of respiratory diseases.